| 1 |
Rudd KE, Johnson SC, Agesa KM, et al. Global, regional, and national sepsis incidence and mortality, 1990-2017: analysis for the global burden of disease study[J]. Lancet, 2020, 395 (10219): 200-211.
|
| 2 |
L'Heureux M, Sternberg M, Brath L, et al. Sepsis-induced cardiomyopathy: a comprehensive review[J]. Curr Cardiol Rep, 2020, 22 (5): 35.
|
| 3 |
Xin Y, Ge Y, Chang L, et al. Risk factors of postoperative septic cardiomyopathy in perioperative sepsis patients[J]. BMC Anesthesiol, 2022, 22 (1): 193.
|
| 4 |
Hollenberg SM, Singer M. Pathophysiology of sepsis-induced cardiomyopathy[J]. Nat Rev Cardiol, 2021, 18 (6): 424-434.
|
| 5 |
Ahmed MM, Zaki A, Alhazmi A, et al. Identification and validation of pathogenic genes in sepsis and associated diseases by integrated bioinformatics approach[J]. Genes (Basel), 2022, 13 (2): 209.
|
| 6 |
Dana AH, Alejandro SP. Role of sulforaphane in endoplasmic reticulum homeostasis through regulation of the antioxidant response[J]. Life Sci, 2022, 299: 120554.
|
| 7 |
汤鲁明,王林霞,孙来芳,等.萝卜硫素对脓毒症急性肺损伤大鼠氧化损伤及脱嘌呤/脱嘧啶核酸内切酶1表达的影响[J/OL].中华危重症医学杂志(电子版),2017,10(4):246-251.
|
| 8 |
汤鲁明,徐俊南,林海鸟,等.萝卜硫素对脓毒症相关急性肾损伤大鼠氧化应激损伤的保护作用[J/OL].中华危重症医学杂志(电子版),2021,14(3):187-191.
|
| 9 |
Ehrman RR, Sullivan AN, Favot MJ, et al. Pathophysiology, echocardiographic evaluation, biomarker findings, and prognostic implications of septic cardiomyopathy: a review of the literature [J]. Crit Care, 2018, 22 (1): 112.
|
| 10 |
Parker MM, Shelhamer JH, Bacharach SL, et al. Profound but reversible myocardial depression in patients with septic shock[J]. Ann Intern Med, 1984, 100 (4): 483-490.
|
| 11 |
Sato R, Sanfilippo F, Lanspa M, et al. Sepsis-induced cardiomyopathy: mechanism, prevalence, assessment, prognosis, and management[J]. Chest, 2025, 168 (6): 1383-1394.
|
| 12 |
Fan D, Wu R. Mechanisms of the septic heart: from inflammatory response to myocardial edema[J]. J Mol Cell Cardiol, 2024, 195: 73-82.
|
| 13 |
Otoo RA, Allen AR. Sulforaphane's multifaceted potential: from neuroprotection to anticancer action[J]. Molecules, 2023, 28 (19): 6902.
|
| 14 |
Schepici G, Bramanti P, Mazzon E. Efficacy of sulforaphane in neurodegenerative diseases[J]. Int J Mol Sci, 2020, 21 (22): 8637.
|
| 15 |
Li Y, Qin K, Liang W, et al. Kidney injury in a murine hemorrhagic shock/resuscitation model is alleviated by sulforaphane's anti-inflammatory and antioxidant action[J]. Inflammation, 2024, 47 (6): 2215-2227.
|
| 16 |
Ren J, Jiang X, Yu G, et al. Sulforaphane ameliorates DSS-induced colitis and secondary liver injury in mice: proposed mechanism in the SCFAs-FFAR2/3-macrophage polarization axis[J]. J Nutr Biochem, 2026, 150: 110239.
|
| 17 |
Sun Y, Zhou S, Guo H, et al. Protective effects of sulforaphane on type 2 diabetes-induced cardiomyopathy via AMPK-mediated activation of lipid metabolic pathways and NRF2 function[J]. Metabolism, 2020, 102: 154002.
|
| 18 |
Bi CF, Liu J, Yang LS, et al. Research progress on the mechanism of sepsis induced myocardial injury[J]. J Inflamm Res, 2022, 15: 4275-4290.
|
| 19 |
Wiger CW, Ranheim T, Arnesen H, et al. TLR4 inhibition attenuated LPS-induced proinflammatory signaling and cytokine release in mouse hearts and cardiomyocytes[J]. Immun Inflamm Dis, 2025, 13 (1): e70133.
|
| 20 |
Gao X, Cai S, Li X, et al. Sepsis-induced immunosuppression: mechanisms, biomarkers and immunotherapy[J]. Front Immunol, 2025, 16: 1577105.
|
| 21 |
Kuroshima T, Kawaguchi S, Okada M. Current perspectives of mitochondria in sepsis-induced cardiomyopathy[J]. Int J Mol Sci, 2024, 25 (9): 4710.
|
| 22 |
于紫英,刘峰涛,曾勇智.线粒体功能障碍与脓毒症心肌病的研究进展[J].中国心血管杂志,2024,29(6):593-596.
|
| 23 |
李玉玲,康健,冯卓.脓毒症心功能障碍的研究进展[J/OL].中华危重症医学杂志(电子版),2017,10(3):200-206.
|
| 24 |
Hou TT, Yang HY, Wang W, et al. Sulforaphane inhibits the generation of amyloid-β oligomer and promotes spatial learning and memory in Alzheimer's disease (PS1V97L) transgenic mice[J]. J Alzheimers Dis, 2018, 62 (4): 1803-1813.
|
| 25 |
Wang W, Mu S, Yan D, et al. Comprehending toll-like receptors: pivotal element in the pathogenesis of sepsis and its complications[J]. Front Immunol, 2025, 16: 1591011.
|
| 26 |
苏小燕,阮仙利,柯海艳,等.斑点型锌指结构蛋白介导Toll样受体/核因子κB信号通路调控肺炎大鼠肺组织损伤的机制研究[J/OL].中华危重症医学杂志(电子版),2025,18(3):182-188.
|
| 27 |
迪丽热巴·吐尔逊,杨春波,丁琼莉,等. β受体阻滞剂阻断TLR4炎症通路减轻脓毒症心肌损伤的研究[J].中华急诊医学杂志,2022,31(10):1353-1360.
|
| 28 |
Zhou D, Zhu Y, Ouyang MZ, et al. Knockout of Toll-like receptor 4 improves survival and cardiac function in a murine model of severe sepsis[J]. Mol Med Rep, 2018, 17 (4): 5368-5375.
|
| 29 |
Hadi SMH, Majeed S, Ghafil FA, et al. Effect of sulforaphane on cardiac injury induced by sepsis in a mouse model: role of toll-like receptor 4[J]. J Med Life, 2023, 16 (7): 1120-1126.
|
| 30 |
Wang S, He S, Hu X, et al. Nrf2 mediated signaling axis in sepsis-induced cardiomyopathy: potential pharmacological receptor[J]. Inflamm Res, 2025, 74 (1): 76.
|
| 31 |
徐桂萍,朱倩倩,杨振宇.富马酸二甲酯减轻糖尿病大鼠心肌缺血再灌注损伤及其相关机制研究[J/OL].中华危重症医学杂志(电子版),2021,14(2):100-106.
|
| 32 |
Fang Z, Wang G, Huang R, et al. Astilbin protects from sepsis-induced cardiac injury through the NRF2/HO-1 and TLR4/NF-κB pathway[J]. Phytother Res, 2024, 38 (2): 1044-1058.
|
| 33 |
Ma C, Gu C, Lian P, et al. Sulforaphane alleviates psoriasis by enhancing antioxidant defense through KEAP1-NRF2 pathway activation and attenuating inflammatory signaling[J]. Cell Death Dis, 2023, 14 (11): 768.
|
| 34 |
Pan J, Wang R, Pei Y, et al. Sulforaphane alleviated vascular remodeling in hypoxic pulmonary hypertension via inhibiting inflammation and oxidative stress[J]. J Nutr Biochem, 2023, 111: 109182.
|